LabCorp Developing Options to Prioritize COVID-19 Testing for Inpatient Population in Support of Guidance from the White Hous...
March 23 2020 - 9:07AM
Business Wire
Company also preparing to support faster
point-of-care testing for COVID-19 in hospitals once
available
LabCorp (NYSE: LH), a leading global life services company that
is deeply integrated in guiding patient care, today announced that
it is exploring all options to prioritize COVID-19 testing for the
hospital inpatient population who are being treated for what the
physician suspects may be the COVID-19 virus. The company
anticipates finalizing options through the week and will
subsequently work with hospitals to begin implementation.
LabCorp continues to add capacity to perform testing for
patients who should be tested in accordance with Centers for
Disease Control and Prevention (CDC) and other health authority
guidelines.
“LabCorp colleagues around the world are working tirelessly
alongside our industry partners and governmental and health
authorities to increase testing and capacity,” said Adam Schechter,
president and CEO of LabCorp. “We are aligned with the
Administration’s guidance and are actively encouraging all
healthcare providers to follow the guidance to prioritize testing
for patients who are hospitalized and being treated for suspected
COVID-19. We are exploring all options to make this happen and will
continue to do all we can to help fight this unprecedented health
crisis.”
LabCorp is also preparing to help hospitals for whom it provides
technical support services to perform on-site serological and
molecular tests for COVID-19, including Cepheid’s recently
announced Xpert Xpress SARS-CoV-2 molecular test, once available.
LabCorp remains in close contact with manufacturers that are
developing additional test options, and will work with healthcare
providers to help them prepare to use these tests when they become
available.
LabCorp continues to play a vital role in supporting the public
response to COVID-19 and has moved quickly to increase its testing
capacity by adding staff, equipment and more high-throughput
testing. On Friday, March 20, LabCorp announced that it has the
ability to perform more than 20,000 COVID-19 tests per day. This
represents a significant increase in capacity since the company
released its COVID-19 test on March 5, 2020. The company is working
continuously to support the needs of healthcare workers, patients,
government, clients and other organizations, and expects capacity
to continue to increase.
LabCorp is now performing COVID-19 testing in three of its
largest labs in the country.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostics solutions,
brings innovative medicines to patients faster, and uses technology
to improve the delivery of care. LabCorp reported revenue of more
than $11.5 billion in 2019. To learn more about LabCorp, visit
www.LabCorp.com, and to learn more about Covance Drug Development,
visit www.Covance.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including but not limited to statements with respect to clinical
laboratory testing. Each of the forward-looking statements is
subject to change based on various important factors, many of which
are beyond the Company’s control, including without limitation,
competitive actions and other unforeseen changes and general
uncertainties in the marketplace, changes in government
regulations, including healthcare reform, customer purchasing
decisions, including changes in payer regulations or policies,
other adverse actions of governmental and third-party payers, the
Company’s satisfaction of regulatory and other requirements,
patient safety issues, changes in testing guidelines or
recommendations, adverse results in material litigation matters,
failure to maintain or develop customer relationships, our ability
to develop or acquire new products and adapt to technological
changes, failure in information technology, systems or data
security, and employee relations. These factors, in some cases,
have affected and in the future (together with other factors) could
affect the Company’s ability to implement the Company’s business
strategy and actual results could differ materially from those
suggested by these forward-looking statements. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements. The Company has no obligation to
provide any updates to these forward-looking statements even if its
expectations change. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Further
information on potential factors, risks and uncertainties that
could affect operating and financial results is included in the
Company’s most recent Annual Report on Form 10-K and subsequent
Forms 10-Q, including in each case under the heading RISK FACTORS,
and in the Company’s other filings with the SEC.
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200323005358/en/
LabCorp Media: Pattie Kushner — 336-436-8263
Media@LabCorp.com
Investors: Clarissa Willett —
336-436-5076 Investor@LabCorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024